Alpha Tau Medical Ltd, a health care company based in Wilmington, Delaware, USA, has recently marked a significant milestone in its operations. The company, which specializes in the development and manufacturing of medical devices, particularly focuses on diffusing alpha-emitters radiation therapy for the conformal treatment of solid tumors. This innovative approach serves patients globally, and further details about their products and services can be accessed on their website, www.alphatau.com . Alpha Tau Medical is publicly traded on the Nasdaq stock exchange under the ticker symbol DRTS.
On December 10, 2025, Alpha Tau Medical announced its inaugural brain-tumor treatment, a development that could represent a pivotal shift for the biotech firm. This announcement is particularly noteworthy as it underscores the company’s commitment to advancing cancer treatment technologies. The successful implementation of this treatment could potentially enhance the company’s reputation and market position within the healthcare sector.
Financially, Alpha Tau Medical’s stock has experienced notable fluctuations over the past year. As of January 1, 2026, the company’s share price closed at $4.83. Throughout the previous 52 weeks, the stock price ranged from a low of $2.30 on April 3, 2025, to a high of $5.206 on December 16, 2025. This range indicates a significant upward trajectory, with the current price approximately 68% above the year-low and 7% below the year-high. These figures suggest a moderate recovery from earlier volatility, with the stock price stabilizing within a relatively narrow band.
The company’s market capitalization stands at approximately $411.83 million USD, reflecting its valuation in the healthcare sector. The recent therapeutic achievement in brain-tumor treatment may bolster investor confidence, potentially influencing the stock’s performance within its current price corridor. As Alpha Tau Medical continues to innovate and expand its treatment offerings, it remains a key player in the medical device industry, particularly in the realm of radiation therapy for cancer treatment.
